Vor Biopharma
Vor Biopharma develops telitacicept, a dual-target fusion protein for autoimmune diseases.
SCHEDULE 13G/AAug 14Latest SEC filing
Jul 7Latest story
July 2026
Sign inSign inVor Biopharma develops telitacicept, a dual-target fusion protein for autoimmune diseases.